Mar 21 |
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
|
Mar 20 |
Journey Medical FY Earnings Preview
|
Mar 19 |
Journey Medical (DERM) Up as FDA Accepts Skin Disease Drug NDA
|
Mar 18 |
Journey Medical announces U.S. FDA acceptance of NDA for its rosacea treatment
|
Mar 18 |
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
|
Mar 15 |
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
|
Mar 13 |
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference
|
Mar 11 |
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
|
Mar 8 |
Journey Medical Insiders Up US$187k On US$520.8k Investment
|
Feb 26 |
Journey Medical (DERM) to Report Q4 Earnings: What's in the Cards?
|